US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of ...

Boosting the endocannabinoid 2-AG in the brain can counteract opioid addiction while preserving their pain relief, a Weill ...

Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...

Only about 27% of patients newly diagnosed with focal epilepsy are seizure-free on initial anti-seizure medications, new ...

Investing.com - The US economy added more jobs than anticipated in November, rebounding after job growth almost stalled during the prior month, impacted by devastating recent hurricanes and ...

As anti-obesity medications gain popularity, a new concern has also gained traction among researchers: increased food waste. A self-administered online survey sponsored by Ohio State found that 25 ...

This article updates the previously published evidence of the clinical effectiveness of anti-TNF-α drugs in CD; however, it differs from previous reviews in several respects. First, it was not ...

After the recent revelation that Pete Hegseth had secretly paid a financial settlement to a woman who had accused him of raping her in 2017, President-elect Donald Trump stood by his choice of ...

Anxiety can cause physical symptoms like chest pain. While it may be reasonable to assume that a heart attack is to blame, around 58% of cases have nothing at all to do with the heart but are rather ...

The scientific development’s potential is huge, according to Han. It could mean the creation of new anti-anxiety drugs that are much more targeted than the ones currently available — and ...

“It can, potentially, create a whole new class of drugs that can more specifically target anxiety disorder,” he says. These would differ from common anti-anxiety medications by more ...